​
​

Enliven Therapeutics (ELVN) Stock Forecast, Price Target & Predictions

OverviewRevenueFinancialsChart

ELVN Stock Forecast

Enliven Therapeutics stock forecast is as follows: an average price target of $39.50 (represents a 55.45% upside from ELVN’s last price of $25.41) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

ELVN Price Target

The average price target for Enliven Therapeutics (ELVN) is $39.50 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $40.00 to $39.00. This represents a potential 55.45% upside from ELVN's last price of $25.41.

ELVN Analyst Ratings

Buy

According to 3 Wall Street analysts, Enliven Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ELVN stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Enliven Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 15, 2024Colleen KusyRobert W. Baird$40.00$24.0566.32%57.42%
Sep 23, 2024Salim SyedMizuho Securities$39.00$23.8063.87%53.48%
Jun 10, 2024Colleen KusyRobert W. Baird$32.00$22.5841.72%25.93%
Apr 09, 2024Salim SyedMizuho Securities$34.00$18.3085.79%33.81%
Row per page
Go to

The latest Enliven Therapeutics stock forecast, released on Nov 15, 2024 by Colleen Kusy from Robert W. Baird, set a price target of $40.00, which represents a 66.32% increase from the stock price at the time of the forecast ($24.05), and a 57.42% increase from ELVN last price ($25.41).

Enliven Therapeutics Price Target by Period

1M3M12M
# Anlaysts124
Avg Price Target$40.00$39.50$36.25
Last Closing Price$25.41$25.41$25.41
Upside/Downside57.42%55.45%42.66%

In the current month, the average price target of Enliven Therapeutics stock is $40.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 57.42% increase as opposed to Enliven Therapeutics's last price of $25.41. This month's average price target is up 1.27% compared to last quarter, and up 10.34% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Sep 09, 2024H.C. Wainwright-BuyInitialise
Aug 14, 2024Cowen & Co.BuyBuyHold
Apr 25, 2022SVB LeerinkMarket PerformMarket PerformHold
Row per page
Go to

Enliven Therapeutics's last stock rating was published by H.C. Wainwright on Sep 09, 2024. The company Initialise its ELVN rating from "null" to "Buy".

Enliven Therapeutics Financial Forecast

Enliven Therapeutics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
# Analysts-------
Surprise %-------

Enliven Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ELVN's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Enliven Therapeutics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EBITDA-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

undefined analysts predict ELVN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Enliven Therapeutics's previous annual EBITDA (undefined) of $NaN.

Enliven Therapeutics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
Net Income-------
Avg Forecast$-28.96M$-31.05M$-28.00M$-26.87M$-25.22M$-23.99M$-26.44M
High Forecast$-28.96M$-31.05M$-28.00M$-26.87M$-23.32M$-23.99M$-26.44M
Low Forecast$-28.96M$-31.05M$-28.00M$-26.87M$-28.55M$-23.99M$-26.44M
Surprise %-------

Enliven Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ELVN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Enliven Therapeutics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
SG&A-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

Enliven Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ELVN last annual SG&A of $NaN (undefined).

Enliven Therapeutics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EPS-------
Avg Forecast$-0.60$-0.64$-0.58$-0.56$-0.52$-0.50$-0.55
High Forecast$-0.60$-0.64$-0.58$-0.56$-0.48$-0.50$-0.55
Low Forecast$-0.60$-0.64$-0.58$-0.56$-0.59$-0.50$-0.55
Surprise %-------

According to undefined Wall Street analysts, Enliven Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ELVN previous annual EPS of $NaN (undefined).

Enliven Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
PMVPPMV Pharmaceuticals$1.61$18.001018.01%Buy
IMRXImmuneering$2.11$17.50729.38%Buy
GOSSGossamer Bio$0.66$3.75468.18%Buy
AVTEAerovate Therapeutics$2.61$13.00398.08%Hold
CMPXCompass Therapeutics$1.38$5.00262.32%Buy
GPCRStructure Therapeutics$30.10$92.40206.98%Buy
LYRALyra Therapeutics$0.18$0.50177.78%Hold
CGEMCullinan Oncology$12.22$31.50157.77%Buy
ELYMEliem Therapeutics$5.11$13.00154.40%Buy
CELCCelcuity$12.73$31.50147.45%Buy
REPLReplimune Group$11.05$24.20119.00%Buy
KRONKronos Bio$0.87$1.6387.36%Buy
ELVNEnliven Therapeutics$25.41$39.5055.45%Buy
MLTXMoonLake Immunotherapeutics$51.86$79.3352.97%Buy

ELVN Forecast FAQ

Is Enliven Therapeutics a good buy?

Yes, according to 3 Wall Street analysts, Enliven Therapeutics (ELVN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of ELVN's total ratings.

What is ELVN's price target?

Enliven Therapeutics (ELVN) average price target is $39.5 with a range of $39 to $40, implying a 55.45% from its last price of $25.41. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Enliven Therapeutics stock go up soon?

According to Wall Street analysts' prediction for ELVN stock, the company can go up by 55.45% (from the last price of $25.41 to the average price target of $39.5), up by 57.42% based on the highest stock price target, and up by 53.48% based on the lowest stock price target.

Can Enliven Therapeutics stock reach $40?

ELVN's average twelve months analyst stock price target of $39.5 does not support the claim that Enliven Therapeutics can reach $40 in the near future.

What is Enliven Therapeutics's current price target trend?

1 Wall Street analyst forecast a $40 price target for Enliven Therapeutics (ELVN) this month, up 57.42% from its last price of $25.41. Compared to the last 3 and 12 months, the average price target increased by 55.45% and increased by 42.66%, respectively.

What are Enliven Therapeutics's analysts' financial forecasts?

Enliven Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-75.647M (high $-73.744M, low $-78.978M), average SG&A $0 (high $0, low $0), and average EPS is $-1.569 (high $-1.53, low $-1.638). ELVN's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-115M (high $-115M, low $-115M), average SG&A $0 (high $0, low $0), and average EPS is $-2.38 (high $-2.38, low $-2.38).